• Home
  • Our Technology
  • Research & Development
  • Products & Services
  • About Us
    • CN
    R & D
    Cancer
    Origin-specific metabolic fingerprints for cancer diagnosis
    A systems biology disease

    Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. Environmental pollution, unhealthy lifestyle, genetic factors, population ageing and low cure rate by traditional treatment are the main factors contributing to the high incidence of cancer.

    Cancer is a complex disease that involves a sequence of gene-environment interactions in a progressive process. Early diagnostics for cancers are limited. Exact tumor screening technologies are desperately needed.

    The majority of tumor biology research has concentrated on how signaling pathways and transcription factors control tumor growth and cell cycle. However, there has been renewed interest in how metabolic changes contribute to the occurrence and progression of malignant tumors in recent years.


    Advances in Cancer Metabolomics Research

    One of the key factors in tumorigenesis is altered metabolism. Metabolic reprogramming precedes tumor development, whereas metabolic abnormalities precede clinical evidence of tumor. Many factors influence cancer cell metabolism, including tumor hypoxia, matrix composition, immune cell infiltration, and genetic alterations.

    Tumor is now regarded as a metabolic disease. Abnormalities and changes in metabolic pathways can reflect tumor status in real time and with high sensitivity. As a result, the use of metabolomics will open up new avenues for early tumor detection.


  • Metabolic Abnormality
  • Stromal Elements
  • Gene Alterations
  • Tumor
    Hypoxia
    • Cancer Research and Development

    We have reasons to believe that metabolomics has the potential to transform oncology, with applications ranging from screening to diagnosis and prognosis.


    1. Compile Metabolic Data

    We’ve been actively accumulating metabolic databases of multiple cancers, with detailed information of sub-types and stages.

    2. Early Diagnosis Model

    We use machine learning and AI to build models for cancer diagnosis and screening.

    3. Clinical Validation

    Promising molecular markers will go through analytical and clinical validation in a large general population.

    The incidence rate of cancer continues to rise
    The demand for biomarkers will increase significantly

    We aim to build a pan-cancer molecular detection test with high sensitivity and specificity for high-risk populations enabling early detection and early treatment.

    Early tumor screening is still a "blue ocean" market, and the existing market is relatively undeveloped in comparison to the future incremental market.

    According to some researchers, the Chinese market will reach $100 billion in the next ten years, with enormous potential.


  • High Sensitivity
  • High Specificity
  • Efficient and Economical
    • News
    2023-12-12
    Overseas Conference | Bio Europe, expedited innovation and partnership establishment
    Metanotitia team attended the BIO-EUROPE 2022 Conference in Leipzig, Germany. Metanotitia, a global leader in metabolomics technology, shared its experience and achievements in metabolomics application in cancer biomarker development at this meeting.
    2022-11-04
    Machine learning (ML) in metabolomics
    The application of machine learning (ML) techniques in the field of metabolomics has been instrumental in driving the development of metabolomics research. With the increasing sensitivity of mass spectrometric devices, the number of untargeted features ex
    2021-11-10
    A brief history of the development and working principle of mass spectrometry in the past century
    Metabolomics, as the closest omics to phenotype in systems biology, has grown in popularity in recent years in the field of life science.Because of the wide range of metabolites with different properties and concentrations, such as amino acids, sugars, or
    2021-07-06
    Spring Festival blessings for 2021
    Looking back on the three-year development path, maitu takes "pursuing the best metabolomics and serving the best healthy life" as its vision, and "improving human health and welfare" as its goal.
    2021-02-05
    Metabolomics around us: the skin
    The skin is the largest organ in the human body, accounting for about 16% of body weight. The skin consists of the dermis and the epidermis: the epidermis is the outer layer of the skin and consists of the stratum corneum, the stratum hyaline, the stratum
    2020-06-09
    About Us
    Pursuit the Best Metabolomics, Empower People to Live Their Best Lives
    Learn More
    Parternships and Collaborations

    Are you looking to establish strategic collaboration or partnership opportunity in cancer research with an innovative and progressive research company?  We are interested in collaborations with leading researchers, institutions, and facilities with proven track records. Contact us or leave your message below.

    Metanotitia Inc.

  • Service hotline

    0451-51021416

  • E-mail

    Info@metanotitia.com

  • Address

    HQ: Floor 3-4, Building C4, Building 6, Science and Technology Headquarters, Shenzhen (Harbin) Industrial Park, Zhigu Street, Songbei District, Harbin
    BO: Room 1307,13F Beike Building, Nanshan District,Shenzhen
    • Contact Us
    • Please confirm the information given above is correct, so that we can reach out to you. Metanotitia is committed to protecting and respecting your privacy, and we’ll only use your personal information to administer your account and to provide the products and services you requested.
    Send a message
    TOP